Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Recruiting
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
NCT07765888· Phase 3· Pfizer· Source
Recruiting
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
NCT07733765· Phase 3· Pfizer· Source
Recruiting
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
NCT07429266· Phase 3· Ono Pharmaceutical Co., Ltd.· Source
Contact: Clinical Team
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
NCT07623616· Phase 2· Kyowa Kirin Co., Ltd.· Source
Contact: Kyowa Kirin, Inc.
Recruiting
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
NCT07475806· Phase 2· Astellas Pharma Global Development, Inc.· Source
Contact: Astellas Pharma Global Development, Inc.
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· Phase 2· Eli Lilly and Company· Source
Contact: Kazuhisa Asai (principal investigator)
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Contact: Atsushi Hagihara (principal investigator)
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
NCT07204314· Phase 3· Takeda· Source
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828· Phase 3· Pfizer· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004· Phase 3· argenx· Source
Contact: Yoshiaki Itoh, MD
Active, not recruiting
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711· Phase 3· Pfizer· Source
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Contact: Yasuhiko Deguchi, Site 0010
Active, not recruiting
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033· Phase 3· PharmaEssentia· Source
Active, not recruiting
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983· Phase 2· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source
Recruiting
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
NCT06976944· Phase 2· Yukinori Ozaki· Source
Contact: Shinichiro Kashiwagi
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
NCT06951698· Phase 3· Bristol-Myers Squibb· Source
Contact: Yasuhiko Deguchi, Site 0086
Active, not recruiting
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
NCT06966479· Phase 2· Upstream Bio Inc.· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
NCT06846671· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
NCT06873945· Phase 3· Pfizer· Source
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996· Phase 3· BeOne Medicines· Source
Contact: Study Director
Recruiting
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
NCT06585774· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
NCT06602258· Phase 2· Eisai Inc.· Source
Active, not recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109· Pfizer· Source
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease
NCT06263478· Phase 3· Incyte Biosciences Japan GK· Source
Recruiting
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source
Contact: Shuhei Hosomi (principal investigator)
Active, not recruiting
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
NCT06256328· Phase 2· Ono Pharmaceutical Co., Ltd.· Source
Active, not recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083· Phase 3· Stichting European Myeloma Network· Source
Recruiting
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
NCT05879653· Phase 2· Kyoto University Hospital· Source
Contact: Yuki Kita, MD,PhD
Active, not recruiting
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359· Phase 1· Incyte Corporation· Source
Active, not recruiting
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894· Phase 3· Cytokinetics· Source
Active, not recruiting
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
NCT05995964· Phase 2· Pfizer· Source
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241· Phase 3· Zenas BioPharma (USA), LLC· Source
Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Recruiting
TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer
NCT05646511· Phase 3· National Cancer Center Hospital East· Source
Contact: Kiyoshi Maeda, Dr.
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· Phase 3· Pfizer· Source
Showing 50 of 69.